Understanding bluebird bio’s Operational Performance
In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively, compared to its revenue of $35.43 million in 2017. Meanwhile, peers Amgen (AMGN), Sarepta Therapeutics (SRPT), and Vertex Pharmaceuticals (VRTX) are expected to generate revenues of $23.36 billion, $301.13 million, and $2.99 billion, respectively, in 2018.